RXRA overexpression

The use of drugs targeting the activation or blockade of this target in the analyzed cell lines did not result in changes in cell viability. However, RXRA might be relevant in the disease, pointing to the need for future research testing retinoids and other drugs targeting RXRα for the treatment of ET patients.

The study is currently enrolling patients in the US. Clinical trial information: NCT05929235.

We investigated novel anti-HCC treatments through either the simultaneous inhibition of glycolysis and gluconeogenesis by "phloretin" and "sodium meta-arsenite", respectively (Combination 1); or the concurrent inhibition of glycolysis and induction of gluconeogenesis by phloretin and dexamethasone, respectively, (combination 2). Biochemically, both combinations caused a significant reduction in ATP levels, ALT, and AST activity compared to the other groups. In conclusion, we propose two novel phloretin-based combinations that can be used in treating HCC through the regulation of glucose metabolism and ATP production.

Our findings unravel an unexpected role of transcription factor RXRα in specific miRNA maturation at post-transcriptional level through pre-miRNA binding, and present a mechanistic insight regarding RXRα role in breast cancer progression.

RXRα inversely correlated with mitosis, indicating that RXRα can have a role in proliferation control. VDR and RXRα may participate in the development of melanocytic lesions and be a future target of new studies and directed therapies.

Importantly, RXRA OE also led to the disruption of the oxidative capacity of these cells. Combining IM with clinically available RXRA ligands could form an alternative treatment strategy in CML patients with suboptimal response to IM.

We then assessed the sensitivity to other TKIs nilotinib and dasatinib in the RXRA OE cells and found increased sensitivity...Next we assessed the effect of clinically available ligands specific to RXRA (Acitretin,Bexarotene and 9-cis-Retinoic acid) on CML CD34+ cells in combination with IM...Interestingly RXRA OE reduced the engraftment potential of CML cells in-vivo, indicating a mechanism for altering the stemness capacity of CML cells. Further work is ongoing to elucidate the molecular mechanisms orchestrated by RXRA in CML cells.